雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Prescribing Patterns for Anti-Parkinsonian Drugs in Japan: Prescription-Based Database Study Tetsuya Maeda 1 , Atsushi Hattori 2 , Junki Yamamoto 2 , Ken Tsunekawa 2 , Shigehisa Ibe 3 , Futoshi Kinoshita 2 1Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University 2Medical Affairs Department, Ono Pharmaceutical Co., Ltd. 3Claims Data Development Group, Planning and Development Department, Japan Medical Information Research Institute, Inc. Keyword: パーキンソン病 , L-ドパ , L-ドパ補助薬 , アドヒアランス , 調剤レセプトデータベース , Parkinson's disease , levodopa , adjuvant to levodopa , adherence , pharmacy claims data pp.273-281
Published Date 2021/3/1
DOI https://doi.org/10.11477/mf.1416201752
  • Abstract
  • Look Inside
  • Reference

Abstract

The current therapeutic approach for Parkinson's disease (PD) is mainly dopamine replacement with levodopa and other anti-parkinsonian drugs. As PD progresses, the number of these drugs used steadily increases. Using prescription-based database for 10 or more years up to October 2019, we investigated actual prescribing patterns for anti-parkinsonian drugs in Japan. The main analyses included data from patients continuously prescribed levodopa for 1 or more years (n=16,270), and of these, those continuously prescribed adjuvants to levodopa for 1 or more years (n=3,675). The results showed that the number of anti-parkinsonian drugs, their daily dose frequencies, and the number of tablets increased over time. These trends were observed not only for levodopa but also for adjuvants to levodopa; the number of adjuvants, their daily dose frequencies and number of tablets also increased. As the daily number of tablets increased, the proportion of dopamine agonists increased. Moreover, as the daily dosage of levodopa increased, the daily number of tablets increased for both overall anti-parkinsonian drugs and adjuvants to levodopa. This study revealed the process of polypharmacy in PD treatment objectively. Our results are valuable for maintaining and improving therapeutic adherence in PD.

(Received 25 August, 2020; Accepted 23 October, 2020; Published 1 March, 2021)


Copyright © 2021, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有